Abstract
Autoimmune diseases are often intractable because their causes are unknown. Identifying which genes contribute to these diseases may allow us to understand the pathogenesis, but it is difficult to determine which genes contribute to disease. Recently, epigenetic information has been considered to activate/deactivate disease-related genes. Thus, it may also be useful to study epigenetic information that differs between healthy controls and patients with autoimmune disease. Among several types of epigenetic information, promoter methylation is believed to be one of the most important factors. Here, we propose that principal component analysis is useful to identify specific gene promoters that are differently methylated between the normal healthy controls and patients with autoimmune disease. Full Automatic Modeling System (FAMS) was used to predict the three-dimensional structures of selected proteins and successfully inferred relatively confident structures. Several possibilities of the application to the drug discovery based on obtained structures are discussed.
Keywords: Autoimmune disease, drug discovery, FAMS, principal component analysis, promoter methylation.
Protein & Peptide Letters
Title:Bioinformatic Screening of Autoimmune Disease Genes and Protein Structure Prediction with FAMS for Drug Discovery
Volume: 21 Issue: 8
Author(s): Shigeharu Ishida, Hideaki Umeyama, Mitsuo Iwadate and Y-h. Taguchi
Affiliation:
Keywords: Autoimmune disease, drug discovery, FAMS, principal component analysis, promoter methylation.
Abstract: Autoimmune diseases are often intractable because their causes are unknown. Identifying which genes contribute to these diseases may allow us to understand the pathogenesis, but it is difficult to determine which genes contribute to disease. Recently, epigenetic information has been considered to activate/deactivate disease-related genes. Thus, it may also be useful to study epigenetic information that differs between healthy controls and patients with autoimmune disease. Among several types of epigenetic information, promoter methylation is believed to be one of the most important factors. Here, we propose that principal component analysis is useful to identify specific gene promoters that are differently methylated between the normal healthy controls and patients with autoimmune disease. Full Automatic Modeling System (FAMS) was used to predict the three-dimensional structures of selected proteins and successfully inferred relatively confident structures. Several possibilities of the application to the drug discovery based on obtained structures are discussed.
Export Options
About this article
Cite this article as:
Ishida Shigeharu, Umeyama Hideaki, Iwadate Mitsuo and Taguchi Y-h., Bioinformatic Screening of Autoimmune Disease Genes and Protein Structure Prediction with FAMS for Drug Discovery, Protein & Peptide Letters 2014; 21 (8) . https://dx.doi.org/10.2174/09298665113209990052
DOI https://dx.doi.org/10.2174/09298665113209990052 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Apoptosis: Potential Therapeutic Targets for New Drug Discovery
Current Medicinal Chemistry A Comparison of Biological Activity of B Lymphocyte Stimulator (BLyS) Antagonist Peptibodies and the Elucidation of Possible BLyS Binding Sites
Protein & Peptide Letters Protein Tyrosine Phosphatase as Potential Therapeutic Target in various Disorders
Current Molecular Pharmacology Role of the Immune System in Autism Spectrum Disorders (ASD)
CNS & Neurological Disorders - Drug Targets Cosignaling Complexity Gets More Convoluted: The Emerging Importance of the B7-Like Butyrophilin Family of Immune Regulators
Current Immunology Reviews (Discontinued) Genetics and Ulcerative Colitis: What are the Clinical Implications?
Current Drug Targets Guar Gum and HPMC Coated Colon Targeted Delivery of 6-Mercapto-Purine
The Natural Products Journal Somatic Genome Variations in Health and Disease
Current Genomics Clinical Applications of Autoimmunity to Citrullinated Proteins in Rheumatoid Arthritis, from Improving Diagnostics to Future Therapies
Recent Patents on Inflammation & Allergy Drug Discovery Modifying TNF alpha for Therapeutic Use A Perspective on the TNF Receptor System
Mini-Reviews in Medicinal Chemistry CD24 in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis: Targeting Redundancy for Immunotherapy?
Current Immunology Reviews (Discontinued) Metformin one in a Million Efficient Medicines for Rheumatoid Arthritis Complications: Inflammation, Osteoblastogenesis, Cardiovascular Disease, Malignancies
Current Rheumatology Reviews HSP60 as a Drug Target
Current Pharmaceutical Design Animal Models of Lupus and Lupus Nephritis
Current Pharmaceutical Design Pernicious Anemia: Fundamental and Practical Aspects in Diagnosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Immunology Behind Tumors: A Mini Review
Current Cancer Therapy Reviews Novel Therapeutic Approaches in Rheumatoid Arthritis: Role of Janus Kinases Inhibitors
Current Medicinal Chemistry miRNA Functions in Arthritis
Current Rheumatology Reviews Antioxidant Therapy for Prevention of Inflammation, Ischemic Reperfusion Injuries and Allograft Rejection
Cardiovascular & Hematological Agents in Medicinal Chemistry Purine Nucleoside Phosphorylase: A Potential Target for the Development of Drugs to Treat T-Cell- and Apicomplexan Parasite-Mediated Diseases
Current Drug Targets